AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph no. 28, page 11-12, with the following amended paragraph:

Though the drug of the invention is sufficiently effective for monotherapy, synergic effects can be obtained by the co-administration of muscarine antagonists having a different action mechanism at the same time or at intervals. A combination drug comprising tamsulosin or its salt, and a muscarinic receptor antagonists can be administered to patients. Muscarinic receptor antagonists include oxybutynin, tolterodine, darifenacin, nubenzepin, zamiphenacine, tiotropium, albamerin, trospium, phesoterozine, temiverine, 3-quinuclidin-3′ -yl-1-phenyl1,2,3, 4-tetrahydroisoquinoline-2-carboxylate(solifenacin), 4 (2-methyl-1H-imidazolyl-1-yl)-2, 2-diphenylbutyl amide, N-[1-(6-aminopyridine-2-ylmethyl) piperidine-4-yl]-2(R)-[3, 3-difluoro-1(R)-cyclopentyl]-2-hydroxyl-2-phenyl acetoamide and their salts. Preferable are M3 receptor-selective antagonists and particularly preferable are succinic acid of (+) - (1S, 3′R) -quinuclidin-3- quinuclidin-3′ -yl 1-phenyl-1, 2, 3, 4-tetrahydroisoquinoline-2-carboxylate (solifenacin).